U.S. Markets closed

Stryker Corporation (SYK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
254.78+0.65 (+0.26%)
At close: 4:04PM EDT
Sign in to post a message.
  • F
    Fighting Irish
    "We are pleased with our results, as business picked up meaningfully in the latter part of the first quarter," said Kevin Lobo, Chairman and Chief Executive Officer. "We expect this momentum to continue and are encouraged by the Wright Medical integration, which is pacing ahead of our expectations."

    Guidance is going to be solid........
  • L
    Loren33498
    Company needs to do a 2:1 or maybe a 3:1 split. their stock would take off afterwards just like TSLA and AAPL after their splits
    Bullish
  • r
    robert
    With vaccinations and economic reopening I see $300 in store for SYK. I've patiently held for several years and the capital returns have finally begun to roll in.
  • B
    Bill mddb
    Bank of America's highest conviction picks for Q2
    Apr. 01, 2021 8:45 AM ETBooking Holdings Inc. (BKNG)By: Clark Schultz, SA News Editor8 Comments

    Bank of America publishes its highest conviction picks list for Q2.
    The firm says the high conviction ideas are based on its views of potential significant market and business-related catalysts that it thinks will affect the stocks in the quarter.
    Eight buy-rated stocks make the list and two underperform-rated stocks are included.
    High-conviction buys: Booking Holdings (NASDAQ:BKNG), Disney (NYSE:DIS), Newmont (NYSE:NEM),NXP Semiconductors (NASDAQ:NXPI), O'Reilly Auto (NASDAQ:ORLY), Parker Hannifin (NYSE:PH), Schlumberger (NYSE:SLB) and Stryker Corp (NYSE:SYK).
    High conviction underperforms: Dollar Tree (NASDAQ:DLTR) and Iron Mountain (NYSE:IRM).
  • D
    Dave
    Top pick on BNN market call this week. Lots of elective surgeries have been on hold, but as vaccines ramp up and economies improve, elective surgeries will ramp up quickly. And this sp will rise in concert.
  • F
    Fighting Irish
    Beat on Rev's $4Billion vs $3.96Billion !
  • F
    Fighting Irish
    Ex-Dividend Date Mar 30, 2021
    1y Target Est 253.04
  • T
    T
    Conformis CFMS better company for knee replacements. SYK off the shelf knee replacement joints not as good as personalized knee replacements designed for your individual bone structure
  • P
    PSH
    Miss of 6 cents on earnings 1.93 vs est 1.99
  • W
    Wing
    Peaked, down from here
    Bearish
  • R
    Rick
    I first began buying SYK back in 2003 on the advice of an orthopedist friend of mine. I believe there's was one split in shares in 2004. Been purchasing ever since. Some of my shares I purchased in low - mid $30 range. Have been purchasing since. Today own close to 16,000 shares. Have sold shares infrequently over the last 15 years. Has been my best investment.
  • M
    Matthew
    Stryker is a stealthy frothy growth stock...kudos to management!
  • M
    MarketMania
    $MESO conversation
    To All New MESO shareholders and stem cell / MESO naysayers – a lot of us long-time shareholders (Minnesota, Left-e, Seanpierre1, Josephine, Frank/ Tarentella 123, Francesca, George, etc..) have been involved with Osiris for a very long time – some as early as the IPO, and others that have bought over the years. I first bought Osiris in 2011 after a lot of research and continued to buy over a period of years. When Osiris partnered with Mesoblast in October 2013, it was a huge disappointment in my mind – but in hindsight, is was a great decision by Peter Friedli. Peter knew that taking Prochymal – Remestemcel-L to market would have required a lot of capital/dilution. This enabled Osiris to focus on Grafix, GrafixPL, Stravix, etc. Peter was excellent at choosing the right partner for Osiris’ technology/science. NuVasive, Inc. $NUVA for Osteocel, Stryker Corporation $SYK for BIO4, Arthrex for BIO4, etc. until Smith & Nephew $SNN bought our Osiris in March of 2019. Peter was a co-founder of the Osiris along with Kevin Kimberlin. I would suggest EVERYONE search Kevin’s website – first and last name together dot com – to understand his background. I know some long term shareholders who had the opportunity to meet Kevin in the past at Osiris’ shareholders meetings. He is a very intelligent individual and his background is VERY IMPRESSIVE. The SCIENCE is ready for PRIME TIME. Anyone looking at the small sample size of the Covid-19 trial – need to look at the past trials and the success to draw any conclusions. Many of us have had the opportunity to tour Osiris’ headquarters in Maryland – their walls were lined with children that were saved by their SCIENCE. That was their motivation! Peter knew when to partner with the right company. We’ll see when/if MESO will partner with big pharma – hopefully it’s north of $75/share. Until then, do your own research and understand the science/history. We’re at a critical stage of stem cell therapies and MESO is the BEST horse in the race. Disclaimer: long a lot of $ATHX too! …. And the $MDXG Cheerleaders deserve a shout out to – you shouldn’t have drank Pete’s Kool-Aid and listened to Beef, Peter, Wendy, Frozen, BrianX, Homebuilder, etc. – they’re all clueless and people that follow them - continue to miss a great opportunity!
  • B
    Bimal
    When a company loses as much in market cap as the company they are acquiring, then you know that the street has overreacted. It is not as if the new business they are buying has $0. Go look at Abbv, BMY - both received similar treatment and people who bought those stocks after the haircut are up very nicely. For those saying that SYK overpaid, WMGI has been trading at similar levels in the past - the company being acquired is not just going to agree to the current share price. Also, none of us management - they might see a lot of different things - synergy, fending off competition, new areas of growth etc. Medical field is so daunting - you just don't create a gizmo and start selling it - there is a huge barrier to entry due to all the certifications etc. I have enjoyed very nice growth in SYK over the years - will double down - every time, I have seen this 10% down moves, the stock has recovered - just go look at the 5 year chart.
  • R
    Roderick
    I said a major announcement was coming last month (check my history), No announcements, however, their website has quietly changed. Notice anyone missing from the management team photos?
  • B
    BoningRizal
    What is happening with SYK. 3 investment houses downgraded SYK namely, Goldman Sachs, Citi and Morgan Stanley. Should I sell?
  • P
    PSH
    Love this company, bought in around 170 a few months back. They have a strong record of increasing shareholder value and price. Absolutely love the long term growth and prospects for this company, even as it captures more market share every year. In saying that I will be adding to this sometime in early 2021 as I do feel that it has some bumps in the road over the next two quarters as more and more elective surgeries (which they specialize in) are being rescheduled due to the second round of lockdowns in Canada and the U.S. The price has run up and not taken into account these elective surgeries being rescheduled, so it should be corrected. The price will reflect this short term problem, but fundamentals of this company and it’s balance sheet are awesome. It is because of this I feel there is going to be a great entry point in the short term, and once Covid is more controlled the sky's the limit for this company. Keep a close eye on this one as a great entry point will arise in the near term and once you buy and hold, you will not regret it!
  • K
    Kevin
    I bought the dip, anyone else? This company simply buys and conquers the market.
  • T
    Techfan20
    $OSIR conversation
    Grafix (wound product) is currently pulling the $OSIR train, yet BIO4 holds huge potential in bone market.
    BIO4 revenue is growing consistently and at an accelerating pace (compared the same quarter year earlier):
    Q3 2017 21%
    Q4 2017 23%
    Q1 2018 27%
    Q2 2018 54%
    BIO4 is distributed by $SYK, keep up the good work!
  • J
    Johan
    Who should SYK acquire next?